PathoQuest specializes in advanced biosafety testing and biologics characterization through its innovative iDTECT® platform, which utilizes Next Generation Sequencing (NGS) technology. This platform is designed to enhance the safety and efficacy of biologics by providing rapid and reliable quality control assessments. PathoQuest's NGS assays are recognized for their ability to replace traditional in vivo and in vitro testing methods, offering a faster, safer, and animal-free alternative for viral safety testing and genetic characterization. The company’s services cater to a wide range of modalities, including monoclonal antibodies, viral vectors, cell therapies, and vaccines, thereby supporting the biopharmaceutical industry in navigating complex regulatory environments.

In addition to its NGS capabilities, PathoQuest offers a comprehensive suite of services that includes adventitious virus testing, identity confirmation, and cell line characterization. These services are crucial for ensuring the biosafety and quality of biologics throughout the development and manufacturing processes. The company emphasizes its commitment to ethical testing practices and regulatory compliance, positioning itself as a trusted partner for biopharmaceutical companies looking to advance their therapeutic products while maintaining high safety standards. Through strategic partnerships and a dedicated team of experts, PathoQuest aims to transform the future of biologic therapies and significantly impact patient care.

France

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

PathoQuest

Company Details